Novo Nordisk Looks To Increase Its Global GLP-1 Lead
Strategy Includes Cementing Dominance In Obesity As Sales Growth Flattened In Q2
Novo Nordisk said it extended its global lead in the GLP-1 space during Q2 and outlined a strategy to dominate the growing market obesity market as its pipeline grows.
